Journal article
Dinutuximab for maintenance therapy in pediatric neuroblastoma
American journal of health-system pharmacy, Vol.74(8), pp.563-567
04/15/2017
DOI: 10.2146/ajhp160228
PMID: 28389455
Abstract
The pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.
Dinutuximab (Unituxin, United Therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma. Its approval has led to the first major change in standard recommended first-line maintenance therapy for high-risk pediatric neuroblastoma in over a decade. Dinutuximab causes antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity by binding to GD2, a tumor-associated antigen. The recommended dosage of dinutuximab is 17.5 mg/m
/day for 4 consecutive days of each 24- or 32-day cycle, for a maximum of 5 cycles. In a Phase III trial, patients who received dinutuximab as part of combination immunotherapy in addition to standard maintenance therapy had significantly improved 2-year event-free survival relative to those who received standard maintenance therapy alone (66% versus 46%,
< 0.01). Dinutuximab has a unique adverse-effect profile that includes infusion reactions, neuropathic pain, and electrolyte abnormalities; the most common adverse effects observed with dinutuximab use in clinical trials were pain, pyrexia, myelosuppression, infusion reactions, and electrolyte abnormalities.
Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.
Details
- Title: Subtitle
- Dinutuximab for maintenance therapy in pediatric neuroblastoma
- Creators
- Lauren McGinty - University of Wisconsin HealthJill Kolesar - University of Kentucky
- Resource Type
- Journal article
- Publication Details
- American journal of health-system pharmacy, Vol.74(8), pp.563-567
- DOI
- 10.2146/ajhp160228
- PMID
- 28389455
- ISSN
- 1079-2082
- eISSN
- 1535-2900
- Language
- English
- Date published
- 04/15/2017
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984695796102771
Metrics
1 Record Views